Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. November 2022 16:05 ET | Quelle: IO Biotech

IO Biotech Announces Third Quarter Results for 2022

Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company’s global Phase 3 combination trial of IO102-IO103 and KEYTRUDA®...
03. November 2022 08:00 ET | Quelle: IO Biotech

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
31. Oktober 2022 08:00 ET | Quelle: IO Biotech

IO Biotech to Participate in the Jefferies London Healthcare Conference

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
13. Oktober 2022 16:05 ET | Quelle: IO Biotech

IO Biotech Announces Appointment of New Chief Financial Officer

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
05. Oktober 2022 08:05 ET | Quelle: IO Biotech

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
06. September 2022 07:30 ET | Quelle: IO Biotech

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
11. August 2022 17:00 ET | Quelle: IO Biotech

IO Biotech Announces Second Quarter Results for 2022

Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanomaAnnounced initiation and...
06. Juni 2022 08:00 ET | Quelle: IO Biotech

IO Biotech to Participate in the 2022 BIO International Convention

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
26. Mai 2022 17:00 ET | Quelle: IO Biotech

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
23. Mai 2022 08:00 ET | Quelle: IO Biotech

IO Biotech to Participate in the Jefferies Healthcare Conference

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...

Vorherige Seite

Nächste Seite